logo
  

Humana Affirms FY22 Adj. EPS Outlook - Update

While reporting financial results for the third quarter on Wednesday, health insurer Humana Inc. (HUM) affirmed its adjusted earnings guidance for the full-year 2022, which was raised at the company's Investor Day in September 2022.

For fiscal 2022, the company now projects earnings of about $23.27 per share and adjusted earnings of about $25.00 per share.

Previously, the company expected earnings of about $23.08 per share and adjusted earnings of about $25.00 per share.

On average, 21 analysts polled by Thomson Reuters expect the company to report earnings of $25.03 per share for the year. Analysts' estimates typically exclude special items.

The company also said its operating performance reinforces its confidence in achieving its new 2025 adjusted earnings target of $37.00 per share.

The company also anticipates 2023 individual Medicare Advantage membership growth of 325,000 to 400,000, or 7.1 percent to 8.7 percent growth.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT